Cutaneous mucormycosis in an immunocompromised patient.
Becker
B C
BC
Dr v Haunersches Children's Hospital, LMU Munich, Germany. benjamin.becker@med.uni-muenchen.de
Schuster
F R
FR
Ganster
B
B
Seidl
H P
HP
Schmid
I
I
D020095:Absidia / Q000187:drug effects / Q000254:growth & development / Q000302:isolation & purification*; D000293:Adolescent; D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D009091:Mucormycosis / Q000175:diagnosis* / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications / Q000188:drug therapy / Q000276:immunology; D016896:Treatment Outcome; D014945:Wound Healing
D000935:Antifungal Agents; D000970:Antineoplastic Agents; D000666:Amphotericin B